Choosing drugs for UK COVID-19 treatment trials

Chinnery, Patrick F., Bonnet, Marion ORCID: https://orcid.org/0000-0002-7559-2413, Cave, Alison, Hofer, Matthias P., Lamb, Alastair, McConkey, Glenn A., Medcalf, Nicholas, Smith, Stephen P., Tsakok, Teresa, Watson, Robert, Webster, Steve and You, Tao 2021. Choosing drugs for UK COVID-19 treatment trials. Nature Reviews Drug Discovery 10.1038/d41573-021-00203-7

Preview	PDF - Accepted Post-Print Version Download (276kB) | Preview
Preview	PDF - Supplemental Material Download (327kB) | Preview

Abstract

In 2020, the UK government funded a portfolio of platform trials to develop new treatments for COVID-19. A key feature was the independent prioritization of candidate drugs with central coordination to prevent duplication, accelerating recruitment to deliver definitive trial results. A similar approach could be used for non-communicable diseases where treatment advances have been limited.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Nature Research
ISSN:	1474-1776
Date of First Compliant Deposit:	23 February 2022
Last Modified:	06 Nov 2024 16:45
URI:	https://orca.cardiff.ac.uk/id/eprint/146157

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item